3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 2
2
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Colorectal Cancer Metastatic
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Merkel Cell
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Capecitabine
6
Bevacizumab
5
trifluridine tipiracil drug combination
3
Cetuximab
3
Oxaliplatin
2
sintilimab
1
monoclonal antibody YYB-101
1
aflibercept
1
Vemurafenib
1
Nivolumab
1
LY-2157299
1
Irinotecan
1
HMPL-013
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Colorectal Cancer Metastatic
×
aflibercept
×
Clear all
NCT01955629
2016-04-18
AMOR
Sanofi
Phase 1/2
Terminated
4 enrolled
7 charts